Kineta Cash on Hand 2014-2024 | KANT
Kineta cash on hand from 2014 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Kineta Annual Cash on Hand
(Millions of US $) |
| 2023 |
$6 |
| 2022 |
$13 |
| 2021 |
$11 |
| 2020 |
$85 |
| 2019 |
$15 |
| 2018 |
$118 |
| 2017 |
$75 |
| 2016 |
$86 |
| 2015 |
$14 |
| 2014 |
$9 |
| 2013 |
$3 |
Kineta Quarterly Cash on Hand
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$2 |
| 2023-12-31 |
$6 |
| 2023-09-30 |
$8 |
| 2023-06-30 |
$8 |
| 2023-03-31 |
$9 |
| 2022-12-31 |
$13 |
| 2022-09-30 |
$8 |
| 2022-06-30 |
$13 |
| 2022-03-31 |
$17 |
| 2021-12-31 |
$11 |
| 2021-09-30 |
$46 |
| 2021-06-30 |
$56 |
| 2021-03-31 |
$63 |
| 2020-12-31 |
$85 |
| 2020-09-30 |
$41 |
| 2020-06-30 |
$49 |
| 2020-03-31 |
$57 |
| 2019-12-31 |
$15 |
| 2019-09-30 |
$78 |
| 2019-06-30 |
$88 |
| 2019-03-31 |
$105 |
| 2018-12-31 |
$118 |
| 2018-09-30 |
$46 |
| 2018-06-30 |
$61 |
| 2018-03-31 |
$64 |
| 2017-12-31 |
$75 |
| 2017-09-30 |
$44 |
| 2017-06-30 |
$58 |
| 2017-03-31 |
$70 |
| 2016-12-31 |
$86 |
| 2016-09-30 |
$100 |
| 2016-06-30 |
$43 |
| 2016-03-31 |
$50 |
| 2015-12-31 |
$14 |
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
$9 |
| 2013-12-31 |
$3 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
